Ligand acquires Ab Initio Biotherapeutics for $12 millionin cash
Ligand announces the signing of an agreement with Ab Initio Biotherapeutics whereby Ligand will acquire Ab Initio for $12 million in cash. Ab Initio was a privately held antigen-discovery company based in South San Francisco, California. July 23, 2019